Mass Drug Administration Initiative Launched to Combat Lymphatic Filariasis in 13 Endemic States
Click to start listening
Synopsis
On February 10, Union Health Minister J P Nadda launched the nationwide Mass Drug Administration campaign targeting Lymphatic Filariasis in 13 states. The initiative aims to eliminate the disease by 2027 through free medication distribution to over 17.5 crore people.
Key Takeaways
- Mass Drug Administration (MDA) launched in 13 states.
- Over 17.5 crore people targeted for free medication.
- Focus on community involvement to eliminate Lymphatic Filariasis.
- Medicines include DEC and Albendazole to combat the disease.
- Safety guidelines for medication consumption highlighted.
New Delhi, Feb 10 (NationPress) Reinforcing its pledge to eradicate Lymphatic Filariasis by 2027, Union Minister for Health and Family Welfare J P Nadda initiated the yearly nationwide Mass Drug Administration (MDA) campaign on Monday in 13 designated endemic states.
The MDA effort will encompass 111 endemic districts across 13 states: Andhra Pradesh, Assam, Bihar, Chhattisgarh, Gujarat, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Uttar Pradesh, and West Bengal.
Starting today, the filaria prevention medications will be distributed door-to-door and provided “free of cost to more than 17.5 crore individuals across 111 endemic districts,” Nadda stated during the campaign launch via video conference.
Lymphatic Filariasis, often referred to as “Hathi Paon”, is a parasitic infection spread by infected mosquitoes. It can result in physical disabilities including lymphoedema (swelling of the limbs) and hydrocele (swelling of the scrotum), imposing long-term challenges on affected individuals and their families.
“Our commitment is to achieve an LF-free India, and realizing this objective necessitates the involvement of every citizen and active community participation. With a shared sense of duty, we can eliminate Lymphatic Filariasis, ensuring safety for millions,” remarked Nadda.
Directed by the National Center for Vector Borne Diseases Control (NCVBDC) under the Ministry of Health, the MDA campaign includes medication regimens: double Drug Regimen (DA): Diethylcarbamazine Citrate (DEC) and Albendazole; and triple Drug Regimen (IDA): Ivermectin, Diethylcarbamazine Citrate (DEC), and Albendazole.
The medications function to inhibit the spread of LF by eradicating the microscopic filarial parasites present in the bloodstream of infected persons, thus preventing further transmission by mosquitoes.
The Union Health minister urged residents in these regions “to take the medicines, safeguarding themselves and their families from this crippling disease.”
“The endemic districts must guarantee that over 90 percent of the eligible population consumes anti-filaria medications. Our collective commitment and resolve will transform lives and secure a future devoid of Lymphatic Filariasis,” Nadda added.
Although the MDA medication is highly safe and effective, it should not be taken on an empty stomach. Children under 2 years, pregnant women, and seriously ill individuals should avoid these drugs.
